Charcot-Marie-Tooth Disease Clinical Trials

Find Charcot-Marie-Tooth Disease Clinical Trials Near You

Deciphering MORC2 Genotype/Phenotype Correlation to Improve Patient Diagnostic

Status: Recruiting
Location: See all (12) locations...
Intervention Type: Diagnostic test
Study Type: Observational
SUMMARY

The Microrchidia CW-type zinc finger 2 (MORC2) gene encodes a protein expressed in all tissues and enriched in the brain. It is involved in Charcot-Marie-Tooth disease, with mire than 30 families presenting MORC2 mutations. Recently, MORC2 mutation have been shown to be responsible for more complex phenotypes like DIFGAN: developmental delay, impaired growth, dysmorphic facies and axonal neuropathy. Different mutations are responsible from a diverse spectrum of phenotype, from CMT to DIFGAN. MORC2 is involved, through its ATPase activity, in DNA repair, chromatin remodeling and epigenetic silencing via the Human silencing hub (HUSH) complex. Our hypothesis is that the hypo- or hyper-activation of the HUSH complex by different MORC2 mutations could be responsible for different phenotypes in patients. The aim of this study is to perform a genotype-phenotype correlation study in patients presenting MORC2 mutations.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 4
Healthy Volunteers: f
View:

• Presence of a mutation in the MORC2 gene, identified during an evaluation for peripheral neuropathy or intellectual disability

• Patient has undergone electromyography (EMG) or is able to undergo EMG during the inclusion visit

• Affiliation with the national health insurance system

• Informed consent from the patient if an adult, or from parents/legal guardians if the patient is a minor

Locations
Other Locations
France
CHU de Besançon
RECRUITING
Besançon
CHRU Brest
RECRUITING
Brest
CHU Grenoble
RECRUITING
Grenoble
CH de Versailles
RECRUITING
Le Chesnay
Service de Génétique moléculaire, pharmacogénétique, hormologie Hôpital Bicêtre
RECRUITING
Le Kremlin-bicêtre
Hospices Civils de Lyon
RECRUITING
Lyon
CHU Marseille
RECRUITING
Marseille
CHU de Nantes
RECRUITING
Nantes
CH Pitié Salpêtrière
RECRUITING
Paris
Hôpital Necker
RECRUITING
Paris
CHU de Saint-Etienne
RECRUITING
Saint-etienne
CHU Strasbourg
RECRUITING
Strasbourg
Contact Information
Primary
Shams RIBAULT, MD
shams.ribault@chu-lyon.fr
00334 72 07 25 73
Time Frame
Start Date: 2026-06-16
Estimated Completion Date: 2027-06
Participants
Target number of participants: 45
Treatments
Charcot-Marie-Tooth patients : Patients presenting with length-dependent sensitive-motor axonal neur
Patients presenting with length-dependent sensitive-motor axonal neuropathy
DIFGAN patients
Patients presenting with DIFGAN syndrome : developmental delay, impaired growth, dysmorphic facies and axonal neuropathy
Control
Control group without any neurological disorder
Related Therapeutic Areas
Sponsors
Leads: Hospices Civils de Lyon

This content was sourced from clinicaltrials.gov